|
業務類別
|
Biotechnology |
|
業務概覽
|
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101. |
| 公司地址
| 1200 Page Mill Road, Palo Alto, CA, USA, 94304 |
| 電話號碼
| +1 650 281-0850 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.kodiak.com |
| 員工數量
| 109 |
| Dr. Victor Perlroth, M.D. |
Chief Executive Officer and Chairman of the Board |
美元 756.60K |
22/04/2025 |
| Mr. John A. Borgeson |
Executive Vice President, Chief Financial Officer, Secretary and Principal Accounting Officer |
美元 525.03K |
22/04/2025 |
|
|
| Mr. Robert A. Profusek |
Lead Independent Director |
22/04/2025 |
| Dr. Taiyin Yang, PhD |
Independent Director |
22/04/2025 |
| Dr. Felix J. Baker,PhD |
Independent Director |
22/04/2025 |
| Dr. Richard S. Levy,M.D. |
Independent Director |
22/04/2025 |
| Mr. Charles A. Bancroft |
Independent Director |
22/04/2025 |
| Dr. Bassil I. Dahiyat, PhD. |
Independent Director |
22/04/2025 |
| Dr. Victor Perlroth, M.D. |
Chief Executive Officer and Chairman of the Board |
22/04/2025 |
|
|
|
|
